These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36284643)

  • 1. Achievements of primary prevention targets in individuals with high risk of cardiovascular disease: an 8-year follow-up of the Tromsø study.
    Hagen AN; Ariansen I; Hanssen TA; Lappegård KT; Eggen AE; Løchen ML; Njølstad I; Wilsgaard T; Hopstock LA
    Eur Heart J Open; 2022 Sep; 2(5):oeac061. PubMed ID: 36284643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type 1 diabetes management: Room for improvement.
    Varkevisser RDM; Birnie E; Mul D; van Dijk PR; Aanstoot HJ; Wolffenbuttel BHR; van der Klauw MM
    J Diabetes; 2023 Mar; 15(3):255-263. PubMed ID: 36808864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment target achievement after myocardial infarction and ischaemic stroke: cardiovascular risk factors, medication use, and lifestyle: the Tromsø Study 2015-16.
    Hopstock LA; Morseth B; Cook S; Eggen AE; Grimsgaard S; Lundblad MW; Løchen ML; Mathiesen E; Nilsen A; Njølstad I
    Eur J Prev Cardiol; 2022 Mar; 29(2):362-370. PubMed ID: 33778888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register.
    Karlsson SA; Franzén S; Svensson AM; Miftaraj M; Eliasson B; Andersson Sundell K
    BMC Health Serv Res; 2018 Nov; 18(1):900. PubMed ID: 30486824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors Associated With Achievement of Blood Pressure, Low-Density Lipoprotein Cholesterol (LDL-C), and Glycemic Targets for Primary Prevention of Cardiovascular Diseases Among High Cardiovascular Risk Malaysians in Primary Care.
    Baharudin N; Ramli AS; Ramland SS; Badlie-Hisham NI; Mohamed-Yassin MS
    J Prim Care Community Health; 2023; 14():21501319231191017. PubMed ID: 37551146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults.
    Palmer MJ; Machiyama K; Woodd S; Gubijev A; Barnard S; Russell S; Perel P; Free C
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD012675. PubMed ID: 33769555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applying the evidence: do patients with stroke, coronary artery disease, or both achieve similar treatment goals?
    Saposnik G; Goodman SG; Leiter LA; Yan RT; Fitchett DH; Bayer NH; Casanova A; Langer A; Yan AT; ; ;
    Stroke; 2009 Apr; 40(4):1417-24. PubMed ID: 19213947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achievement of low-density lipoprotein cholesterol targets in Chinese patients with atherosclerotic cardiovascular disease after receiving statins and ezetimibe.
    Cheng Y; Dong S; Shen P; Sun Y; Lin H; Zhai S
    Front Cardiovasc Med; 2022; 9():988576. PubMed ID: 36312234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults.
    Palmer MJ; Barnard S; Perel P; Free C
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012675. PubMed ID: 29932455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mode of treatments and achievement of treatment targets among type 2 diabetes patients with different comorbidities - a register-based retrospective cohort study in Finland.
    Nazu NA; Wikström K; Lamidi ML; Lindström J; Tirkkonen H; Rautiainen P; Laatikainen T
    BMC Prim Care; 2022 Nov; 23(1):278. PubMed ID: 36352358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological management of modifiable cardiovascular risk factors (blood pressure and lipids) following diagnosis of myocardial infarction, stroke and diabetes: comparison between population-based studies in Russia and Norway.
    Cook S; Hopstock LA; Eggen AE; Bates K; Iakunchykova O; Kontsevaya A; McKee M; Schirmer H; Voevoda M; Kudryavtsev AV; Malyutina S; Leon DA
    BMC Cardiovasc Disord; 2020 May; 20(1):234. PubMed ID: 32430002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ANICHKOV study: the effect of combined hypotensive and lipid-lowering therapy on cardiovascular complications in patients of high and very high risk.
    Sergienko IV; Ansheles AA; Drapkina ОМ; Gornyakova NB; Zubareva MY; Shepel RN; Kuharchuk VV; Boytsov SA
    Ter Arkh; 2019 May; 91(4):90-98. PubMed ID: 31094482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary prevention care and effect: Total and low-density lipoprotein cholesterol levels and lipid-lowering drug use in women and men after incident myocardial infarction - The Tromsø Study 1994-2016.
    Hopstock LA; Eggen AE; Løchen ML; Mathiesen EB; Njølstad I; Wilsgaard T
    Eur J Cardiovasc Nurs; 2018 Aug; 17(6):563-570. PubMed ID: 29488799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations Between Intake of Fermented Dairy Products and Blood Lipid Concentrations Are Affected by Fat Content and Dairy Matrix - The Tromsø Study: Tromsø7.
    Machlik ML; Hopstock LA; Wilsgaard T; Hansson P
    Front Nutr; 2021; 8():773468. PubMed ID: 34881281
    [No Abstract]   [Full Text] [Related]  

  • 15. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study.
    Banegas JR; López-García E; Dallongeville J; Guallar E; Halcox JP; Borghi C; Massó-González EL; Jiménez FJ; Perk J; Steg PG; De Backer G; Rodríguez-Artalejo F
    Eur Heart J; 2011 Sep; 32(17):2143-52. PubMed ID: 21471134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment and control of BP and lipids in patients with hypertension and additional risk factors.
    Welch V; Tang SS
    Am J Cardiovasc Drugs; 2007; 7(5):381-9. PubMed ID: 17953476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling.
    Perera R; McFadden E; McLellan J; Lung T; Clarke P; Pérez T; Fanshawe T; Dalton A; Farmer A; Glasziou P; Takahashi O; Stevens J; Irwig L; Hirst J; Stevens S; Leslie A; Ohde S; Deshpande G; Urayama K; Shine B; Stevens R
    Health Technol Assess; 2015 Dec; 19(100):1-401, vii-viii. PubMed ID: 26680162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women's Atorvastatin Trial on Cholesterol (WATCH).
    McPherson R; Angus C; Murray P; Genest J;
    Am Heart J; 2001 Jun; 141(6):949-56. PubMed ID: 11376309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular disease across Europe.
    Halcox JP; Tubach F; Lopez-Garcia E; De Backer G; Borghi C; Dallongeville J; Guallar E; Medina J; Perk J; Sazova O; Sweet S; Roy C; Banegas JR; Rodriguez-Artalejo F
    PLoS One; 2015; 10(2):e0115270. PubMed ID: 25692692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is a treat-to-target approach to lipid-lowering therapy appropriate in patients with chronic kidney disease? A prospective French cohort study.
    Massy ZA; Kolla E; Ferrières J; Bruckert E; Lambert O; Mansencal N; Laville M; Frimat L; Fouque D; Combe C; Pecoits-Filho R; Stengel B; Liabeuf S;
    J Nephrol; 2021 Oct; 34(5):1467-1477. PubMed ID: 34117621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.